Androgen Antagonists
Research News and Information

Sunday, November 22, 2009

Sex steroids are necessary in the second postnatal week for the expression of male alloparental behavior in prairie voles (Microtus ochragaster).

29 Sep 2009 Sex steroids play a significant role in organizing male social behavior, which is associated with low levels of pro-social behavior and high levels of aggression. However, the role of steroids in organizing behavior in highly social males is ... Read more...

Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target.

29 Sep 2009 Activation of the androgen receptor is crucial for prostate cancer growth at all points of the illness. Current therapies targeting the androgen receptor, including androgen-depletion approaches and anti-androgens, do not completely inhibit the ... Read more...

Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy.

14 Sep 2009 PURPOSE: The profound hypogonadism due to androgen deprivation therapy for prostate cancer results in complications such as sexual dysfunction, poor quality of life, vasomotor symptoms and altered cognition. Since estrogen is associated with ... Read more...

Latest indexed articles for 'Androgen Antagonists'

These are the very latest articles for this heading:

• Key targets of hormone treatment of prostate cancer. Part I: the androgen receptor and steroidogenic pathways. 30 Oct 2009
• Degarelix (firmagon) for prostate cancer. 17 Oct 2009
• Sex steroids are necessary in the second postnatal week for the expression of male alloparental behavior in prairie voles (Microtus ochragaster). 29 Sep 2009
• Anti-androgens and androgen-depleting therapies in prostate cancer: new agents for an established target. 29 Sep 2009
• Duration of androgen suppression in prostate cancer. 15 Sep 2009
• Editorial comment. 14 Sep 2009
• Lack of an effect of high dose isoflavones in men with prostate cancer undergoing androgen deprivation therapy. 14 Sep 2009
• Intravenous zoledronic acid to prevent osteoporosis in a veteran population with multiple risk factors for bone loss on androgen deprivation therapy. 14 Sep 2009
• Phase II trial of short-term neoadjuvant docetaxel and complete androgen blockade in high-risk prostate cancer. 13 Sep 2009
• Design and synthesis of androgen receptor antagonists with bulky side chains for overcoming antiandrogen resistance. 8 Sep 2009
• [Treatment of hirsutism] 7 Sep 2009
• Inhibition of tumor growth progression by antiandrogens and mTOR inhibitor in a Pten-deficient mouse model of prostate cancer. 6 Sep 2009
• External radiotherapy for prostate cancer with or without androgen deprivation: Geneva, 1991 to 2004. 3 Sep 2009
• External radiotherapy with or without hormonal ablation therapy. 3 Sep 2009
• Circulating cytokine levels in prostate cancer patients undergoing radiation therapy: influence of neoadjuvant total androgen suppression. 30 Aug 2009
• Emerging drugs for prostate cancer. 30 Aug 2009
• Recent advances in the development of selective androgen receptor modulators. 30 Aug 2009
• Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction. 24 Aug 2009
• Pathological effects of prostate cancer correlate with neuroendocrine differentiation and PTEN expression after bicalutamide monotherapy. 12 Aug 2009
• Denosumab in men receiving androgen-deprivation therapy for prostate cancer. 9 Aug 2009

See a longer list of these articles.

Technical information about 'Androgen Antagonists'

Definition: Compounds which inhibit or antagonize the biosynthesis or actions of androgens.

Registry Number: 0

Descriptor UI: D000726

Alternative terms: Androgen Antagonists; Antagonists, Androgen; Antiandrogens;

Allowable Qualifiers: administration & dosage; adverse effects; analysis; blood; cerebrospinal fluid; chemical synthesis; classification; diagnostic use; economics; history; immunology; isolation & purification; metabolism; pharmacokinetics; pharmacology; poisoning; radiation effects; standards; supply & distribution; therapeutic use; toxicity; urine; chemistry; contraindications; agonists;

Tree Number: D06.347.065; D27.505.696.399.450.065;

History Note: 78

Technical Notes: DF: ANDROGEN ANTAG